Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop

National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press.
Psychiatric illnesses – such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) – are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients’ disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts.
Published in:
National Academies of Sciences, Engineering, and Medicine

More Publications

April 18, 2024

Nature Genetics

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

March 5, 2024

Translational Psychiatry

Potential causal association between gut microbiome and posttraumatic stress disorder

January 29, 2024

Scientific Reports

Differential recruitment of brain circuits during fear extinction in non-stressed compared to stress resilient animals

December 29, 2023

Journal of Law and the Biosciences

Defusing the legal and ethical minefield of epigenetic applications in the military, defense, and security context

August 1, 2023

Journal of Psychopharmacology

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

July 29, 2023

Frontiers in Neurology

Models and methods: a perspective of the impact of six IMI translational data-centric initiatives for Alzheimer’s disease and other neuropsychiatric disorders